A significantly lower percentage of patients receiving a 70-mg or 140-mg dose of erenumab had severe disability during treatment compared with placebo.

Erenumab, a fully human monoclonal antibody and inhibitor of the canonical calcitonin gene-related peptide receptor, may reduce migraine disability and improve health-related quality of life (HRQoL) in patients with migraine, according to study results published in Cephalalgia.

Data from patients with migraine participating in a 6-month phase 3 randomized controlled trial were included in the analysis (n=955). In the trial, patients were randomly assigned to once-monthly subcutaneous injections of 70 mg erenumab (n=317), 140 mg erenumab (n=319), or placebo (n=319) and were asked to record their migraine and non-migraine headaches using an eDiary.

Related Articles

A limitation of the analysis includes the reliance on self-reported questionnaire data, which were prone to recall bias.

Findings from this trial support the beneficial impact “of erenumab in reducing the burden of migraine and improving the HRQoL of patients, and confirming its role as a promising new therapy for the prevention of episodic migraine,” the researchers stated.